Lu Zhou

Lu Zhou


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
YLYue Lv
Yue Lv
HSHuiping Shi
Huiping Shi
HLHong Liu
Hong Liu
LZLu Zhou
Lu Zhou
Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder featured by increased platelet destruction and deficient megakaryocyte maturation. First-line treatments include corticosteroids, intravenous immunoglobulin and intravenous anti-D immunoglobulin. Second-line treatments consist of rituximab, thrombopoietin receptor agonists and splenectomy. Although most patients benefit from these treatments, an individualized treatment approach is warranted due to the large heterogeneity among ITP patients. In addition, ITP patients may relapse and there remains a subset of patients who become refractory to treatments. The management of these refractory patients is still a challenge. This review aims to summarize emerging therapeutic approaches for refractory ITP in several categories according to their different targets, including macrophages, platelets/megakaryocytes, T cells, B cells, and endothelial cells. Moreover, current management strategies and combination regimens of refractory ITP are also discussed.

13 May 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
HMHui Mu
Hui Mu
XZXiaojian Zhu
Xiaojian Zhu
HJHui Jia
Hui Jia
LZLu Zhou
Lu Zhou
HLHong Liu
Hong Liu
Although tyrosine Kinase Inhibitors (TKI) has revolutionized the treatment of chronic myeloid leukemia (CML), patients are not cured with the current therapy modalities. Also, the more recent goal of CML treatment is to induce successful treatment-free remission (TFR) among patients achieving durable deep molecular response (DMR). Together, it is necessary to develop novel, curative treatment strategies. With advancements in understanding the biology of CML, such as dormant Leukemic Stem Cells (LSCs) and impaired immune modulation, a number of agents are now under investigation. This review updates such agents that target LSCs, and together with TKIs, have the potential to eradicate CML. Moreover, we describe the developing immunotherapy for controlling CML.

19 April 2018 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
LZLu Zhou
Lu Zhou
MJM. Jiang
M. Jiang
HSH. Shen
H. Shen
TYT. You
T. You
ZDZ. Ding
Z. Ding
LXL. Xia
L. Xia

4 July 2024 in Heliyon
Verified
Journal Article
Open access
YHYudie Huang
Yudie Huang
CWChongyu Wang
Chongyu Wang
HWHua Wang
Hua Wang
HLHong Liu
Hong Liu
LZLu Zhou
Lu Zhou
Multiple myeloma (MM) is a malignancy arisen from the abnormal proliferation of clonal plasma cells. It has a high risk of developing bleeding and thrombotic complications, which are related to poor prognosis and decreased survival. Multiple factors are involved in the breaking of the hemostasis balance, including disease specific factors, patient-specific factors, and drug factors that change pro-and anticoagulant and fibrinolysis. Recently, with the introduction of new treatments such as monoclonal antibodies, chimeric antigen receptor modified T-cell therapy, antibody-drug conjugates directed against BCMA, programmed death-1 inhibitor, export protein 1 inhibitors, histone deacetylase inhibitors, immunomodulatory drugs, proteasome inhibitors and Bcl-2 inhibitors, the therapy of MM patients has entered into a new era. Furthermore, it arouses a question whether these new treatments would alter the hemostasis balance in MM patients, which highlights the importance of the underlying pathophysiology of hemostasis abnormalities in MM, and on prophylaxis approaches. In this review, we updated the mechanisms of hemostasis abnormalities in MM, the impact of the new drugs on hemostasis balance and reliable therapeutic strategies.

4 October 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
HTHong Tian
Hong Tian
LZLu Zhou
Lu Zhou
JDJia‐Wen Dai
Jia‐Wen Dai
YLYun Li
Yun Li
CGCheng‐Yuan Gu
Cheng‐Yuan Gu
JYJie Yin
Jie Yin

23 September 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
YJYizhi Jiang
Yizhi Jiang
JLJizhe Li
Jizhe Li
JHJun Huang
Jun Huang
ZZZichan Zhang
Zichan Zhang
XLXiaocen Liu
Xiaocen Liu
LZLu Zhou
Lu Zhou